London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm, completed its acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. As previously announced, … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged acquisition, Amplimmune, Anthony Brown, anti-PD-L1 mAb, AstraZeneca, autoimmune disease, Ayesha Bharmal, biologics, Cancer, cancer cells, cancer immunology, co-inhibitory molecules, co-stimulatory molecules, Colleen Proctor, Ed Seage, Esra Erkal-Paler, Gaithersburg, immune system, immune-mediated cancer therapy, IMT-C, infectious disease, Jacob Lund, Jens Lindberg, Karl Hård, MEDI-4736, MedImmune, mOX40 mAb, therapeutics, Tracy Rossin, transplantation, tremelimumab
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?